Skip to main content
. 2025 Jan 13;17(2):244. doi: 10.3390/cancers17020244

Figure 2.

Figure 2

SORL1 knockdown inhibits cell proliferation and improves sensitivity of ovarian cancer cell lines to carboplatin. (A) Western blot of SORL1 protein in OVCAR8 ovarian cancer cells transfected with control esiRNA (control) or SORL1-targeting esiRNAs (esiRNA-SORL1) at 48 h post transfection. (B) Cell growth curves of OVCAR8 cells. (C) Western blot of SORL1 protein in KRCH31 cells transfected with control or SORL1-targeting esiRNAs. (D) Cell growth curves of KRCH31 cells. (E) Cell growth curves of OVCAR8 and KRCH31 cells treated with carboplatin. (F) Distribution of OVCAR8 cells in different phases of cell cycle. (G) Caspase-3/7 activity of OVCAR8 and KRCH31 cells treated with 100 μM carboplatin. Two-way ANOVA, * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001, # p < 0.0001.